Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Healthtrust
Chinese Patent Office
Citi
Harvard Business School
Deloitte
Boehringer Ingelheim
UBS

Generated: May 24, 2018

DrugPatentWatch Database Preview

DARIFENACIN HYDROBROMIDE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Darifenacin Hydrobromide patents expire, and what generic alternatives are available?

Darifenacin Hydrobromide is a drug marketed by Alembic Pharms Ltd, Anchen Pharms, Aurobindo Pharma Ltd, Cipla Ltd, Jubilant Generics, and Torrent Pharms Ltd. and is included in six NDAs.

The generic ingredient in DARIFENACIN HYDROBROMIDE is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
Drug patent expirations by year for DARIFENACIN HYDROBROMIDE
Pharmacology for DARIFENACIN HYDROBROMIDE
Synonyms for DARIFENACIN HYDROBROMIDE
(3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-|A-|A-diphenyl-3-pyrrolidineacetamide Hydrobromide
(S)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide hydrobromide
(S)-2-{1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide hydrobromide
[1-[2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL]-3-PYRROLIDNYL]-2,2-DIPHENYLACETAMIDE HYDROBROMIDE
133099-07-7
2-[(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]-3-PYRROLIDINYL]-2,2-DIPHENYLACETAMIDE HYDROBROMIDE
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
2-[(3S)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenyl-acetamide hydrobromide
2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide hydrobromide
3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (3S)-
3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (S)-
3-PYRROLIDINEACETAMIDE, 1-[2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL]-ALPHA,ALPHA-DIPHENYL-, HYDROBROMIDE (1:1), (3S)-
AB0073012
AC-1894
AC1L9FKV
AK326131
AKOS015969311
AN-6905
API0008085
BC003938
BC201082
CAS-133099-07-7
CCG-220969
CHEBI:31455
CHEMBL1200935
CR02EYQ8GV
CS-0380
D01699
Darifenacin (hydrobromide)
darifenacin HBr
Darifenacin hydrobromide (JAN/USAN)
Darifenacin hydrobromide [USAN]
Darifenacin hydrobromide, >=98% (HPLC)
Darifenacin hydrobromide, United States Pharmacopeia (USP) Reference Standard
Darilong
DSSTox_CID_26780
DSSTox_GSID_46780
DSSTox_RID_81899
DTXSID9046780
Enablex (TN)
ENABLEX HYDROBROMIDE
HY-A0012
KS-00000KBH
LS-186532
MCULE-9754914075
MFCD08141803
MolPort-003-846-139
NCGC00168775-01
NCGC00263922-02
PubChem14816
Q-101006
s3144
Tox21_112636
Tox21_112636_1
UK 88525-04 hydrobromide
UK-88525-04
UK-88525-04 (HYDROBROMIDE)
UNII-CR02EYQ8GV
UQAVIASOPREUIT-VQIWEWKSSA-N
W-5366
Z1691545283

US Patents and Regulatory Information for DARIFENACIN HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207681-001 Dec 8, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cipla Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207664-001 Sep 1, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anchen Pharms DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 091190-002 Mar 13, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Torrent Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205209-002 Nov 17, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Fish and Richardson
Accenture
McKinsey
Express Scripts
Federal Trade Commission
Merck
Colorcon
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.